Welcome to our dedicated page for CNS Pharmaceuticals news (Ticker: CNSP), a resource for investors and traders seeking the latest updates and insights on CNS Pharmaceuticals stock.
CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) is a clinical-stage biopharmaceutical company developing anti-cancer drug candidates for primary and metastatic cancers of the brain and central nervous system. The CNSP news feed highlights the company’s announcements about its clinical programs, corporate developments, and interactions with the scientific and investment communities.
A central theme in CNS Pharmaceuticals’ news is the progress of its lead drug candidate, TPI 287. The company issues updates on clinical data, including Phase 1 results in glioblastoma patients treated with TPI 287 in combination with bevacizumab, and discusses the potential of TPI 287 to cross the blood-brain barrier and treat CNS tumors. Releases also describe the breadth of indications in which TPI 287 has been studied, from recurrent glioblastoma and pediatric neuroblastoma to metastatic melanoma and breast cancer metastatic to the brain.
News items also cover scientific visibility, such as acceptance of abstracts for poster presentation at the Society of Neuro-Oncology Annual Meeting. These abstracts, as described by the company, address topics like Berubicin in glioblastoma and pediatric diffuse midline glioma, as well as future evaluation of TPI 287 in CNS diseases. In addition, CNS Pharmaceuticals reports participation in investor conferences and virtual events, where management discusses its development strategy and corporate outlook.
Corporate and governance updates appear in the news as well, including announcements of a 1-for-12 reverse stock split and leadership changes, such as the planned transition of the chief executive officer role to Rami Levin. For investors and observers following CNSP, this news page provides a centralized view of the company’s disclosed milestones in neuro-oncology drug development, capital structure decisions, and executive leadership.
CNS Pharmaceuticals announced receiving regulatory approval from Swissmedic for its pivotal study of Berubicin, aimed at treating recurrent glioblastoma multiforme (GBM). The approval allows for patient enrollment in Switzerland, essential for advancing this promising treatment. The study will randomize approximately 243 patients to evaluate overall survival compared to lomustine, with a pre-planned futility analysis at 30-50% patient completion. Berubicin has gained Fast Track Designation and Orphan Drug Designation from the FDA, enhancing its development prospects.
CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) announced CEO John Climaco's participation in the 2022 Virtual Growth Conference from March 28-30, 2022. Climaco will engage in a live fireside chat on March 30, 2022, at 2:30 PM ET, moderated by Maxim Group's Jason McCarthy. The conference covers diverse sectors and features presentations and Q&As with executives. CNS specializes in novel cancer treatments, including its lead drug candidate Berubicin, aimed at brain cancers. Interested attendees can register on M-Vest.
CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) announced operational and clinical advancements regarding its lead product, Berubicin, in a recent shareholder video. CEO John Climaco expressed frustration with the company's share price fluctuations but emphasized strong patient enrollment in a pivotal study for glioblastoma treatment. Berubicin, a novel anthracycline designed to cross the blood-brain barrier, is currently undergoing trials at various clinical sites globally. The company continues discussions with the FDA to ensure trial advancements, aiming to generate long-term shareholder value.
CNS Pharmaceuticals reported financial results for the year ended December 31, 2021, highlighting a net loss of $14 million, up from $9.5 million in 2020. The increase is attributed to elevated personnel costs and activities for the clinical trial of Berubicin, which received Fast Track Designation and aims to treat recurrent Glioblastoma Multiforme (rGBM). The company also completed a $11.5 million private placement in January 2022 to support ongoing development. Key upcoming milestones include expanding clinical trials and filing an IND for WP1244/WP1874.
CNS Pharmaceuticals (NASDAQ: CNSP) announced participation in the Virtual Investor 2022 Top Picks Conference on January 26, 2022, at 11:00 AM ET. CEO John Climaco will present the company's advancements in treatments for brain and CNS cancers, featuring their lead drug candidate, Berubicin, which effectively crosses the blood-brain barrier. The event will include a corporate presentation and an interactive Q&A session, allowing live and pre-submitted questions from investors. A live webcast will be available, with a replay accessible for one year.
CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) announced the closing of a private placement, raising approximately $11.5 million through the sale of 12,105,264 shares of common stock at $0.95 per share. The accompanying warrants have an exercise price of $0.82 and are valid for five years. The funds from this placement will support clinical trials and general corporate activities. CNS plans to file a registration statement with the SEC within 15 days to cover the resale of shares issued during this transaction.
CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) announced that CEO John Climaco will present at the H.C. Wainwright BioConnect Conference from January 10-13, 2022. The presentation will be available via a video webcast starting January 10 at 7:00 AM ET. CNS Pharmaceuticals focuses on developing innovative treatments for brain and CNS cancers, including the lead drug candidate Berubicin, which targets glioblastoma multiforme.
CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) announced a private placement of approximately $11.5 million by issuing 12,105,264 shares of common stock at $0.95 per share. The placement, led by H.C. Wainwright & Co., is expected to close around January 10, 2022. Proceeds will fund clinical trials, R&D activities, and general corporate purposes. The company will file a registration statement with the SEC within 15 days for the resale of shares. CNSP develops anti-cancer treatments, including its lead drug candidate Berubicin for serious brain cancers.
CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) has received approval from swissethics for a pivotal study of Berubicin, aimed at treating recurrent glioblastoma multiforme (GBM). This study marks a significant milestone, given GBM's aggressive nature. The trial will enroll approximately 243 patients, comparing Berubicin to lomustine to evaluate overall survival. Additionally, the FDA has granted Fast Track Designation and Orphan Drug Designation for Berubicin, which may expedite its development process and provide marketing exclusivity.
CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) announces participation in the Virtual Investor Roundtable Event on November 18, 2021, at 9:00 AM ET. CEO John Climaco and CMO Sandra L. Silberman will present and engage in a moderated discussion followed by a Q&A session. Investors can submit questions live or pre-submit them via the event website. A live video webcast will be available on the company's website, with a replay accessible for one year. CNS specializes in treatments for brain and CNS cancers, focusing on their lead candidate, Berubicin.